All
FDA approves Dysport for therapeutic, aesthetic uses
April 30th 2009Medicis (NYSE:MRX) and Ipsen (Euronext:IPN) announced the U.S. Food and Drug Administration's (FDA) approval of the Biologics License Application (BLA) for DYSPORT (abobotulinumtoxinA), an acetylcholine release inhibitor and a neuromuscular blocking agent, according to GlobeNewswire.com.
Dermatologists readying for enforcement of ‘red flags rule’
April 30th 2009Beginning May 1, the Federal Trade Commission (FTC) was to begin enforcing a rule requiring certain kinds of businesses, including most doctors? practices and hospitals, to develop written plans for identifying and responding to warning signs ? red flags ? of identity theft. And while many healthcare providers view the Red Flags Rule as another time-consuming, expensive federal mandate they have to follow, dermatologists who have prepared for it say it need not be either.
Video: Healthcare reform roundtable debate
April 7th 2009Is the voice of the professional being heard in the debate over healthcare reform? ModernMedicine.com convened a roundtable of doctors, hospital administrators, professors and others to talk about what needs to be done. See the videos at www.modernmedicine.com.
NovaBay, Galderma enter global agreement to develop Aganocide
April 7th 2009Emeryville, Calif. ? NovaBay Pharmaceuticals, which develops anti-infective products for the treatment and prevention of infections without causing resistance, has entered a global agreement with Galderma to develop and commercialize NovaBay's Aganocide, according to a company press release.
Genetic 'master regulator' in skin formation identified
April 7th 2009Corvallis, Ore. ? Oregon State University researchers have discovered a gene in humans that appears to be a master regulator in skin formation, which could shed light on everything from psoriasis to aging skin, according to a University press release.
Valeo partners with Del-Ray for Hydrosal distribution
April 7th 2009Albany, New York ? Valeo Pharma has announced a partnership with Del-Ray Dermatologicals, a subsidiary of Crown Laboratories, for the exclusive sale and distribution of Hydrosal Professional in the U.S, according to a company press release.
Money matters: Balance estate planning, charitable giving with retirement needs
April 2nd 2009Many of our high net-worth clients are finding themselves re-evaluating their annual charitable contributions as well as some of their estate planning goals as they concentrate on meeting their future retirement or current income needs. There are always choices, however, that one can make depending on their priorities and resources.
Schering-Plough drugs may pay off before Merck loses patents
March 12th 2009National report - The purchase of Schering-Plough for 41.1 billion in cash and stock has given Merck a dozen experimental drugs that are nearing marketing approval in the U.S., which may pay off before Merck loses patents on medicines with $8 billion in annual sales, Bloomberg.com reports.
Spain withdraws cervical cancer shot
March 3rd 2009Madrid ? Spanish authorities withdrew 76,000 doses of Gardasil (human papillomavirus quadrivalent vaccine, recombinant, Merck) from the market in February after two teenagers who received the vaccine were hospitalized, according to the news agency Agence France-Presse.
Freebies, farewell: New PhRMA guidelines restrict gifts, permit educational items
March 1st 2009National report - Dermatologists won't miss the free pencils, notepads and posh dinners that new Pharmaceutical Research and Manufacturers of America (PhRMA) guidelines prohibit companies from providing, say physicians contacted by Dermatology Times.
Allergen of the Year: Contact dermatitis group names mixed dialkyl thioureas for 2009
March 1st 2009National report - The North American Contact Dermatitis Group (NACDG) has named mixed dialkyl thioureas as the 2009 Allergen of the Year, according to Bryan E. Anderson, M.D., associate professor of dermatology at Penn State College of Medicine in Hershey, Pa.
At long lash: Cosmetic derms welcome Latisse; still, others worry
March 1st 2009National report - A new prescription product that promotes eyelash growth (Latisse, bimatoprost ophthalmic solution 0.03 percent; Allergan) will benefit cosmetic-minded patients and the dermatologists who serve them, sources say.